# Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer

> **NCT02521077** · PHASE2 · WITHDRAWN · sponsor: **Midwestern Regional Medical Center**

## Conditions studied

- Fatigue

## Interventions

- **DRUG:** Ascorbic Acid
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT02521077
- **Lead sponsor:** Midwestern Regional Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-05
- **Primary completion:** 2019-03
- **Final completion:** 2019-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Manufacturer unwilling to provide information needed for IND application.
- **Last updated:** 2017-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02521077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02521077, "Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02521077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*